ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ CERITINIB TRÊN BỆNH UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ GIAI ĐOẠN IV CÓ ĐỘT BIẾN ALK TẠI BỆNH VIỆN K

Abstract

Objectives: To evaluate the treatment outcomes for patients with non small cell lung cancer stage IV with ceritinib and some adverse events the drug. Patients and method: A retrospective combined prospective study. The patient diagnosed non small cell lung cancer stage IV at Vietnam National Cancer Hospital, from January 2018 to May 2022 treat with ceritinib. Results: 41 patients median age at diagnosis was 49, 53.7% female, 46.3% male. The response rate: 4.9% complete response, 68.3% partial response disease, 14.6% stable disease, 12.2% progression disease. Median progression free survival was 19.9 months (6.2 months-33.6 months). To the adverse events of ceritinib: Diarrhea 73.2% (2.4% at grade 3). Increased ALT, AST were 41.5% (2.4% grade 3). Fatigue 19.5%, abdominal pain 34.1%, nausea 46.3%, neutrophils 2.4%, anemia 7.3% mainly at grade 1, no one had grade 3, 4.